Stay updated with breaking news from Cipla q3 earnings. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- The global active pharmaceutical ingredients market size is estimated to grow by USD 86.47 billion from 2024 to 2028, according to Technavio....
Exelixis, Inc. today announced that it has entered into a Settlement and License Agreement with Cipla Ltd. and Cipla USA, Inc. . This settlement resolves two patent litigations brought by Exelixis...
20.05.2024 - Exelixis, Inc. (Nasdaq: EXEL) today announced that it has entered into a Settlement and License Agreement (Agreement) with Cipla Ltd. and Cipla USA, Inc. (collectively Cipla). This settlement resolves two patent litigations brought by Exelixis in ...
Pearce IP BioBlast w/e 17 May 2024 lexology.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lexology.com Daily Mail and Mail on Sunday newspapers.
JB Pharma, led by CEO Nikhil Chopra, forecasts 12-14% revenue growth and aims to increase Ebitda margins by 27-28% in FY25. The growth is driven by a focus on chronic portfolio, CDMO business expansion, and upcoming acquisition of an ophthalmology drugs portfolio from Novartis. The company's financial performance in FY24 was strong with revenue reaching Rs 3,484 crore.